Conv. Plasma
Nigella Sativa

All curcumin studies
Meta analysis
study COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 86% Improvement Relative Risk Recovery time 21% Curcumin  Ahmadi et al.  EARLY TREATMENT  DB RCT Is early treatment with curcumin beneficial for COVID-19? Double-blind RCT 60 patients in Iran (April - July 2020) Lower hospitalization (p=0.24) and faster recovery (p=0.37), not sig. Ahmadi et al., Food Science and Nutrit.., Jun 2021 Favors curcumin Favors control

Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial

Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226
Jun 2021  
  Source   PDF   All   Meta
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021
*, now known with p = 0.000000046 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.
This is the 4th of 20 COVID-19 RCTs for curcumin, which collectively show efficacy with p=0.0000093.
This is the 7th of 26 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.000000046 (1 in 22 million).
risk of hospitalization, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
recovery time, 20.6% lower, relative time 0.79, p = 0.37, treatment 30, control 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ahmadi et al., 19 Jun 2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 11 authors, study period April 2020 - July 2020.
This PaperCurcuminAll
Oral nano‐curcumin formulation efficacy in the management of mild to moderate outpatient COVID‐19: A randomized triple‐blind placebo‐controlled clinical trial
Reza Ahmadi, Soofia Salari, Mohammad Davood Sharifi, Hamidreza Reihani, Mohammad Bagher Rostamiani, Morteza Behmadi, Zhila Taherzadeh, Saeed Eslami, Seyed Mahdi Rezayat, Mahmoud Reza Jaafari, Sepideh Elyasi
Food Science & Nutrition, doi:10.1002/fsn3.2226
Background: Curcumin, a natural polyphenolic compound, is proposed as a potential treatment option for patients with coronavirus disease by inhibiting the entry of virus to the cell, encapsulation of the virus and viral protease, as well as modulating various cellular signaling pathways. In this study, the efficacy and safety of nanocurcumin oral formulation has been evaluated in patients with mild-moderate Coronavirus disease 2019 (COVID-19) in outpatient setting. Methods: In this triple-blind randomized placebo-controlled clinical trial, sixty mild to moderate COVID-19 patients in outpatient setting who fulfilled the inclusion criteria were randomly allocated to treatment (n = 30) group to receive oral nanocurcumin formulation (Sinacurcumin soft gel which contains 40 mg curcuminoids as nanomicelles), two soft gels twice a day after food for 2 weeks or placebo (n = 30) group. Patients' symptoms and laboratory data were assessed at baseline and during followup period and compared between two groups. Results: All symptoms except sore throat resolved faster in the treatment group and the difference was significant for chills, cough and smell and taste disturbances. The CRP serum level was lower in the treatment group at the end of two weeks and the lymphocyte count was significantly higher in treatment group. No significant adverse reaction reported in the treatment group.
Al-Shamlan, El-Hashim, Bradykinin sensitizes the cough reflex via a B(2) receptor dependent activation of TRPV1 and TRPA1 channels through metabolites of cyclooxygenase and 12-lipoxygenase, Respiratory Research
Babaei, Nassiri-Asl, Hosseinzadeh, Curcumin (a constituent of turmeric): New treatment option against COVID-19, Food Science & Nutrition
Conti, Ronconi, Caraffa, Gallenga, Ross et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARSCoV-2): Anti-inflammatory strategies, J Biol Regul Homeost
Davoudi-Monfared, Rahmani, Khalili, Hajiabdolbaghi, Salehi et al., Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial, Antimicrobial Agents and Chemotherapy
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA
Hashemzadeh, Davoudian, Jaafari, Mirfeizi, The effect of nanocurcumin on the improvement symptoms of knee osteoarthritis: A randomized clinical trial, Current Rheumatology Reviews
Hatamipour, Sahebkar, Alavizadeh, Dorri, Jaafari, Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids, Iran J Basic Med Sci, doi:10.22038/ijbms.2019.32873.7852
Hewitt, Adams, Mazzone, Mori, Yu et al., Pharmacology of bradykinin-evoked coughing in guinea pigs, Journal of Pharmacology and Experimental Therapeutics
Ho, Bryson, Rumsfeld, Medication adherence: Its importance in cardiovascular outcomes, Circulation
Kunnumakkara, Harsha, Banik, Vikkurthi, Sailo et al., Is curcumin bioavailability a problem in humans: Lessons from clinical trials, Expert Opinion on Drug Metabolism & Toxicology
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: Consider cytokine storm syndromes and immunosuppression, Lancet
Moballegh Nasery, Abadi, Poormoghadam, Zarrabi, Keyhanvar et al., Curcumin delivery mediated by bio-based nanoparticles: A review, Molecules
Moghadamtousi, Abdul Kadir, Hassandarvish, Tajik, Abubakar et al., A review on antibacterial, antiviral, and antifungal activity of curcumin, BioMed Research International, doi:10.1155/2014/186864
Pandaran Sudheeran, Jacob, Natinga Mulakal, Gopinathan Nair, Maliakel et al., Safety, tolerance, and enhanced efficacy of a bioavailable formulation of curcumin with fenugreek dietary fiber on occupational stress: A randomized, double-blind, placebo-controlled pilot study, Journal of Clinical Psychopharmacology
Rahimi, Mohammadpour, Dastani, Jafari, Abnous et al., The effect of nanocurcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: A randomized clinical trial, Avicenna J Phytomed
Rao, Regulation of COX and LOX by curcumin, Advances in Experimental Medicine and Biology
Richardson, Griffin, Tucker, Smith, Oechsle et al., Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet
Rodriguez-Morales, Cardona-Ospina, Gutiérrez-Ocampo, Villamizar-Peña, Holguin-Rivera et al., Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel Medicine and Infectious Disease
Roy, Sarkar, Celik, Ghosh, Basu et al., Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?, Phytotherapy Research, doi:10.1002/ptr.6766
Sabermoghaddam, Salari, Hejazi, Amini, Taherzadeh et al., Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial, Phytotherapy Research
Scotton, Chambers, Molecular targets in pulmonary fibrosis: The myofibroblast in focus, Chest
Singh, Aggarwal, Activation of transcription factor NFkappa B is suppressed by curcumin (diferuloylmethane) [corrected, Journal of Biological Chemistry
Tahmasebi, El-Esawi, Mahmoud, Immunomodulatory effects of Nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients, Journal of Cellular Physiology
Valizadeh, Abdolmohammadi-Vahid, Danshina, Gencer, Ammari et al., Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients, International Immunopharmacology, doi:10.1016/j.intimp.2020.107088
Whitehead, Julious, Cooper, Campbell, Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable, Statistical Methods in Medical Research
Wu, Chen, Cai, Zhou, Xu et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Internal Medicine
Zahedipour, Hosseini, Sathyapalan, Majeed, Jamialahmadi, Potential effects of curcumin in the treatment of COVID-19 infection, Phytotherapy Research
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop